Melly M retweeted
Happy and proud to be part of the ENDO-RELIEF project in collaboration with @MMaerklin from @Salihlab supported by the @BMBF_Bund aiming to better understand the development of #endometriosis.
gesundheitsforschung-bmbf.de…
Melly M retweeted
Yesterday Jonas Heitmann successfully defended his #habilitation.
Congratulations on achieving this milestone, Jonas, we look forward to see what is coming next… 🎉 – at Tübingen, Deutschland
Melly M retweeted
🏆Cheers to our Lab Champions!🏅
Ilona Hagelstein: Green jersey for data sprint 📊
Stefanie Müller: Yellow jersey for mouse models 🐭
Samuel Holzmayer: Polka Dot jersey for persistence 🔬
Nisha Prakash: Eddie the Eagle Tricot 🦅
#LabHeroes #ScienceChampions #TourDeForce – at Tübingen, Deutschland
Melly M retweeted
Innovative treatment opportunity @Salihlab @uktuebingen for patients with biochemical recurrence of #prostate #cancer: the bispecific PSMAxCD3 #antibody CC-1.
More information on the Phase I clinical trial at:
medizin.uni-tuebingen.de/de/… – at Tübingen, Deutschland
Melly M retweeted
Today at #CICON23 #Milan:
Melanie Märklin @MMaerklin presented data on the somewhat unexpected role of NFAT1 and NFAT2 in NK cell tumor immunosurveillance. – at Milano, Lombardia
Melly M retweeted
Today at #CICON23 #Milan:
Sylwia Stefańczyk @S_Stefanczyk presented her results on induction of NK cell reactivity against acute myeloid leukemia by FC-optimized B7-H3 antibodies.
#AML #leukemia #Immunotherapy – at Milano, Lombardia
Melly M retweeted
Today at #CICON23 #Milan:
Polina Kaidun reported on specific antiCD16/antiCD3 fusion proteins for targeting NKG2DL in triple negative breast cancer.
#TNBC #Immunotherapy #cancer – at Milano, Lombardia
Melly M retweeted
Today at #CICON23 #Milan:
Samuel Holzmayer demonstrated how NFAT2 regulates susceptibility of #leukemia cells to perforin-mediated killing by cytotoxic lymphocytes.
#Immunotherapy – at Milan, Lombardy
The first day at #CICON23 #Milan has come to an end and it kicked off with an inspiring keynote by 2018 #NobelLaureate in #Medicine @JimAllisonPhD. Now, it’s time to reward ourselves with a well-deserved dinner – #pizza!
@Salihlab @CancerResearch @C_IMT @AACR @ENCI_network
Melly M retweeted
Congratulations to Christopher Hackenbruch for the „Rudolf Schindler“ abstract #award of the #DGVS presenting our FusionVAC22_01 #clinicaltrial for #FLHCC. Pleased to start at @Salihlab with Michael Bitzer, supported by @MedTuebingen @EKFStiftung / #ForTra @Roche #Immunotherapy
Melly M retweeted
Excited to be at #CICON23 in #Milan! 🇮🇹 Ready to dive into the world of #cancer #immunotherapy with experts from around the globe. Let’s explore groundbreaking advancements together! #CancerImmunotherapy #MilanConference @C_IMT @AACR @CancerResearch @Salihlab 🌟🔬🤝 – at Milano, Lombardia
Melly M retweeted
Melanie Märklin @MMaerklin, Polina Kaidun, Sylwia Stefańczyk @S_Stefanczyk and Samuel Holzmayer went to #CICON2023 #Milan to present their work.
I guess one has to conclude that today they are warming up for the meeting by sightseeing…
@C_IMT – at Milano, Lombardia
Melly M retweeted
We are hiring!
Interested in translational #research in cancer #immunotherapy? Explore the positions we have to offer and join the team!
#job #Postdoc #Researcher #PhDStudent #labtechnician
jobs.medizin.uni-tuebingen.d…
jobs.medizin.uni-tuebingen.d…
jobs.medizin.uni-tuebingen.d…
It was a pleasure to celebrate this special moment with all of you 🤩
New day, new festivity! Today we celebrate @MMaerklin‘s defense of her habilitation thesis. Congratulations on this milestone, we are looking forward to see your scientific journey continue 🎉
Melly M retweeted
New day, new festivity! Today we celebrate @MMaerklin‘s defense of her habilitation thesis. Congratulations on this milestone, we are looking forward to see your scientific journey continue 🎉
Melly M retweeted
What is the future of peptide-based #immunotherapy? Our member @JulianeWalz gave interesting insights into #cancer immunotherapy as part of the newest episode of @MedTrib_medizin #podcast 🎙️ "O-Ton #Onkologie" Tune in: bit.ly/3bEajZh (only in 🇩🇪) #CancerResearch
